Active — Not RecruitingNot Applicable

TEZSPIRE (Tezepelumab) Asthma Japan Post-Marketing Study (PMS)

Japan416 participantsStarted 2023-04-04

Plain-language summary

The purpose of the investigation is to confirm the followings under the post-marketing actual long-term use of Tezspire. 1. Development of related AEs 2. Contributing factors possibly having an impact on the safety and effectiveness 3. Development of unexpected related AEs

Who can participate

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * The evaluable patients are those treated with Tezspire for the first time due to "Bronchial asthma (only the patients with severe or intractable bronchial asthma which could not be controlled with the existing therapy) Exclusion Criteria: None

What they're measuring

Incidence of ADRs

Timeframe: 156 weeks

Trial details

NCT IDNCT05729711

SponsorAstraZeneca

Sponsor typeINDUSTRY

Study typeOBSERVATIONAL

Primary completion2029-11-16

View on ClinicalTrials.gov More Bronchial Asthma (Only the Patients With Severe or Intractable Bronchial Asthma Which Could Not be Controlled With the Existing Therapy) trials